BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

418 related articles for article (PubMed ID: 19173370)

  • 21. Serum kynurenic acid is reduced in affective psychosis.
    Wurfel BE; Drevets WC; Bliss SA; McMillin JR; Suzuki H; Ford BN; Morris HM; Teague TK; Dantzer R; Savitz JB
    Transl Psychiatry; 2017 May; 7(5):e1115. PubMed ID: 28463241
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Importance of kynurenine 3-monooxygenase for spontaneous firing and pharmacological responses of midbrain dopamine neurons: Relevance for schizophrenia.
    Tufvesson-Alm M; Schwieler L; Schwarcz R; Goiny M; Erhardt S; Engberg G
    Neuropharmacology; 2018 Aug; 138():130-139. PubMed ID: 29879409
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cortical kynurenine pathway metabolism: a novel target for cognitive enhancement in Schizophrenia.
    Wonodi I; Schwarcz R
    Schizophr Bull; 2010 Mar; 36(2):211-8. PubMed ID: 20147364
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Oral administration of a specific kynurenic acid synthesis (KAT II) inhibitor attenuates evoked glutamate release in rat prefrontal cortex.
    Bortz DM; Wu HQ; Schwarcz R; Bruno JP
    Neuropharmacology; 2017 Jul; 121():69-78. PubMed ID: 28419874
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Manipulation of brain kynurenines: glial targets, neuronal effects, and clinical opportunities.
    Schwarcz R; Pellicciari R
    J Pharmacol Exp Ther; 2002 Oct; 303(1):1-10. PubMed ID: 12235226
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Kynurenate production by cultured human astrocytes.
    Kiss C; Ceresoli-Borroni G; Guidetti P; Zielke CL; Zielke HR; Schwarcz R
    J Neural Transm (Vienna); 2003 Jan; 110(1):1-14. PubMed ID: 12541009
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evaluation of kynurenine pathway metabolism in Toxoplasma gondii-infected mice: implications for schizophrenia.
    Notarangelo FM; Wilson EH; Horning KJ; Thomas MA; Harris TH; Fang Q; Hunter CA; Schwarcz R
    Schizophr Res; 2014 Jan; 152(1):261-7. PubMed ID: 24345671
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Fluctuations in endogenous kynurenic acid control hippocampal glutamate and memory.
    Pocivavsek A; Wu HQ; Potter MC; Elmer GI; Pellicciari R; Schwarcz R
    Neuropsychopharmacology; 2011 Oct; 36(11):2357-67. PubMed ID: 21796108
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [New prospects for antipsychotic treatment - the role of the kynurenine pathway].
    Karakuła-Juchnowicz H; Flis M; Szymona K; Kuczyńska M; Stelmach E; Kowal-Popczak A
    Psychiatr Pol; 2014; 48(6):1167-77. PubMed ID: 25717486
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Kynurenic acid and schizophrenia.
    Erhardt S; Schwieler L; Engberg G
    Adv Exp Med Biol; 2003; 527():155-65. PubMed ID: 15206728
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Acute liver failure increases kynurenic acid production in rat brain via changes in tryptophan metabolism in the periphery.
    Sekine A; Fukuwatari T
    Neurosci Lett; 2019 May; 701():14-19. PubMed ID: 30738081
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Altered serum levels of kynurenine metabolites in patients affected by cluster headache.
    Curto M; Lionetto L; Negro A; Capi M; Perugino F; Fazio F; Giamberardino MA; Simmaco M; Nicoletti F; Martelletti P
    J Headache Pain; 2015; 17(1):27. PubMed ID: 27000870
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [The kynurenic acid hypothesis - a new look at etiopathogenesis and treatment of schizophrenia].
    Flis M; Szymona K; Morylowska-Topolska J; Urbańska A; Krukow P; Kandefer-Szerszeń M; Zdzisińska B; Urbańska EM; Karakuła-Juchnowicz H
    Pol Merkur Lekarski; 2016 Sep; 41(243):160-164. PubMed ID: 27755520
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The kynurenine pathway in schizophrenia and bipolar disorder.
    Erhardt S; Schwieler L; Imbeault S; Engberg G
    Neuropharmacology; 2017 Jan; 112(Pt B):297-306. PubMed ID: 27245499
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Kynurenic acid leads, dopamine follows: a new case of volume transmission in the brain?
    Wu HQ; Rassoulpour A; Schwarcz R
    J Neural Transm (Vienna); 2007 Jan; 114(1):33-41. PubMed ID: 16932989
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Altered kynurenine pathway metabolites in serum of chronic migraine patients.
    Curto M; Lionetto L; Negro A; Capi M; Fazio F; Giamberardino MA; Simmaco M; Nicoletti F; Martelletti P
    J Headache Pain; 2015; 17():47. PubMed ID: 27130315
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Assessment of Prenatal Kynurenine Metabolism Using Tissue Slices: Focus on the Neosynthesis of Kynurenic Acid in Mice.
    Notarangelo FM; Beggiato S; Schwarcz R
    Dev Neurosci; 2019; 41(1-2):102-111. PubMed ID: 31117076
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Kynurenic acid attenuates NMDA-induced pial arteriolar dilation in newborn pigs.
    Bari F; Nagy K; Guidetti P; Schwarcz R; Busija DW; Domoki F
    Brain Res; 2006 Jan; 1069(1):39-46. PubMed ID: 16388784
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Increased levels of kynurenine and kynurenic acid in the CSF of patients with schizophrenia.
    Linderholm KR; Skogh E; Olsson SK; Dahl ML; Holtze M; Engberg G; Samuelsson M; Erhardt S
    Schizophr Bull; 2012 May; 38(3):426-32. PubMed ID: 20729465
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Specific inhibition of kynurenate synthesis enhances extracellular dopamine levels in the rodent striatum.
    Amori L; Wu HQ; Marinozzi M; Pellicciari R; Guidetti P; Schwarcz R
    Neuroscience; 2009 Mar; 159(1):196-203. PubMed ID: 19138730
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.